Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640766 | 0.91 | HDAC1 (0.54) | PKMALOX15MMP12MMP13ALDH1A1 | |
| SCHEMBL5637949 | 0.89 | HDAC1 (0.59) | PKMALOX15KCNA3HDAC1HDAC2 | |
| SCHEMBL5638148 | 0.86 | PKM (0.55) | PKMALOX15ALDH1A1RECQLKCNA3 | |
| SCHEMBL8731217 | 0.85 | PKM (0.46) | PKMALOX15MMP12MMP13ALDH1A1 | |
| SCHEMBL5637944 | 0.84 | HDAC3 (0.51) | ALDH1A1HDAC1HDAC2PLA2G4BMTNR1A | |
| SCHEMBL5638721 | 0.84 | PTPN7 (0.59) | ALDH1A1HDAC1PLA2G4BKDM4EMEN1 | |
| SCHEMBL5641034 | 0.84 | PLA2G4B (0.59) | PKMALOX15ALDH1A1PLA2G4BKMT2A | |
| SCHEMBL8671561 | 0.82 | KCNA3 (0.64) | ALDH1A1RECQLKCNA3HDAC1HDAC2 | |
| SCHEMBL2563648 | 0.82 | ALDH1A1 (0.46) | PKMALDH1A1HDAC1HDAC2PLA2G4B | |
| SCHEMBL16256658 | 0.82 | HDAC1 (0.52) | PKMALDH1A1HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299104-B2 | Melanin hormone antagonist; therapy for obesity, type-2 diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-1711494-B1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7319108-B2 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20070135485-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1723126-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1711494-A1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-6750344-B1 | MONOCYCLIC AMINE SCAFFOLD BEARING AT LEAST TWO SITES OF DIVERSITY, CYCLIZED TO FORM BICYCLIC AMINE SCAFFOLDS; 7-AMINO-PYRROLO(1,2-A)PYRAZIN-4-ONE COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| US-6316626-B1 | Amine compounds and combinatorial libraries comprising same | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4621098-A | Thioethers and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1986-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | CYP11B1, CYP11B2, GPR119 | PKM 638/4885ALOX15 243/4885MMP12 1737/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | PKM 1481/4885ALOX15 610/4885MMP12 983/4885 |
| US-20070135485-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | PKM 2090/4885ALOX15 3315/4885MMP12 2226/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | PKM 2907/4885ALOX15 1817/4885MMP12 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.